← Eichor
Condition: Hepatic Impairment Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hepatic Impairment

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Pharmacokinetics of VC005 Tablets in Subjects With Hepatic Impairment and Normal Hepatic Function
Phase 1 · 1 location(s) · Jiangsu vcare pharmaceutical technology co., LTD · NCT07551557Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Im
Phase 1 · 22 location(s) · Taiho Oncology, Inc. · NCT04953910Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Partici
Phase 1 · 8 location(s) · Eisai Co., Ltd. · NCT04271488Evaluate PK & Safety of Saroglitazar in Subjects With Moderate Hepatic Impairment Due to Cholestatic Liver Disease
Phase 1 · 1 location(s) · Zydus Therapeutics Inc. · NCT06825559A Study to Test How BI 3000202 is Taken up in the Blood of People With and Without Liver Problems
Phase 1 · 1 location(s) · Boehringer Ingelheim · NCT07486102A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Phase 1 · 3 location(s) · GlaxoSmithKline · NCT07358546A Study to Evaluate EDG-7500 in Adults With Hepatic Impairment
Phase 1 · 2 location(s) · Edgewise Therapeutics, Inc. · NCT07324616Hepatic Impairment With Cirrhosis Due to Cholestatic Liver Disease
Phase 1 · 1 location(s) · Zydus Therapeutics Inc. · NCT05045482Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib
Phase 1 · 3 location(s) · SpringWorks Therapeutics, Inc., a healthcare company of Merc · NCT06997276A Phase I Study to Investigate the Effect of Hepatic Impairment of AZD9550 and AZD6234
Phase 1 · 4 location(s) · AstraZeneca · NCT07546760A Study of HDM1002 in Subjects With And Without Varying Degrees Of Hepatic Impairement
Phase 1 · 1 location(s) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · NCT06985615A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
Phase 1 · 3 location(s) · Pfizer · NCT07269301A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants
Phase 1 · 3 location(s) · Bristol-Myers Squibb · NCT07248839e-ALIGN: A Patient Portal-based Intervention to Align Medications With What Matters Most
NA · 1 location(s) · Johns Hopkins University · NCT07454824Pharmacokinetics and Safety Study of Pelabresib in Patients With Advanced Malignancies and Hepatic Impairment
Phase 1 · 8 location(s) · Novartis Pharmaceuticals · NCT07422610Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment
Phase 1 · 1 location(s) · Ascentage Pharma Group Inc. · NCT07282093Pharmacokinetics (PK) and Safety of Zanzalintinib in Participants With Moderate Hepatic Impairment (HI)
Phase 1 · 2 location(s) · Exelixis · NCT06962332A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Modera
Phase 1 · 3 location(s) · Eli Lilly and Company · NCT07165002A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Gr
Phase 2 · 52 location(s) · AbbVie · NCT06682988Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment
Phase 1 · 15 location(s) · Gilead Sciences · NCT04617522The Liver Cirrhosis Cognitive Decline Scale (LiCCoS)
Phase N/A · 1 location(s) · University of Malaya · NCT07418008Pharmacokinetic Study of Vorasidenib in Severe Hepatically Impaired and Matched-Control Participants
Phase 1 · 3 location(s) · Institut de Recherches Internationales Servier (I.R.I.S.) · NCT07250633A Study of Nemtabrutinib in Participants With Moderate Hepatic Impairment (MK-1026-015)
Phase 1 · 3 location(s) · Merck Sharp & Dohme LLC · NCT06442436Study of Bemnifosbuvir/Ruzasvir as a Fixed-dose Combination in Subjects With Normal or Severely Impaired Renal or Hepati
Phase 1 · 2 location(s) · Atea Pharmaceuticals, Inc. · NCT06911320A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment
Phase 1 · 1 location(s) · Taisho Pharmaceutical Co., Ltd. · NCT07231029A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healt
Phase 1 · 3 location(s) · Eli Lilly and Company · NCT07401862A Study to Evaluate the Effect of Moderate or Severe Hepatic Impairment on the Pharmacokinetics (PK) of Inavolisib
Phase 1 · 4 location(s) · Genentech, Inc. · NCT07144111Radiprodil in Participants With Hepatic Impairment
Phase 1 · 2 location(s) · GRIN Therapeutics, Inc. · NCT07457229A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver Problems
Phase 1 · 3 location(s) · Boehringer Ingelheim · NCT07023354A Study to Learn About the Medicine Called PF-08653944 in People With and Without Reduced Liver Function
Phase 1 · 3 location(s) · Pfizer · NCT07519135
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.